William N Whiteley1, Douglas Thompson, Gordon Murray, Geoff Cohen, Richard I Lindley, Joanna Wardlaw, Peter Sandercock. 1. From the Divisions of Clinical Neurosciences (W.N.W., G.C., P.S.) and Neuroimaging Sciences (J.W.), University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; Edinburgh MRC Hub for Trials Methodology Research, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom (D.T., G.M.); and Neurological and Mental Health Division, The George Institute for Global Health, University of Sydney, Sydney, Australia (R.I.L.).
Abstract
BACKGROUND AND PURPOSE: Intravenous recombinant tissue-type plasminogen activator (r-tPA), despite a risk of early symptomatic intracranial hemorrhage (sICH), is of net clinical benefit to acute stroke patients. We tested if predictive models could identify patients least likely to be harmed by sICH or those who gained no net benefit. METHODS: We used the Third International Stroke Trial (IST-3) trial data set, an international, multicenter, open treatment randomized trial of 0.9 mg/kg r-tPA versus control in 3035 patients with acute ischemic stroke. We compared the discrimination and calibration of previously developed predictive models for ICH and poststroke poor outcome and developed a new model using variables selected by systematic review. We calculated the absolute and relative risk reduction of death or dependency with r-tPA in patients at a low, medium, or high predicted risk of sICH or poor functional outcome. RESULTS: Prediction models for sICH or poor outcome (Hemorrhage After Thrombolysis [HAT]; Sugar, Early Infarct Signs, Dense Artery, Age, National Institutes of Health (NIH) Stroke Score (SEDAN); Glucose Race Age Sex Pressure Stroke Severity [GRASPS]; Stroke Thrombolytic Predictive Instrument; Dense Artery, Rankin Score, Age, Glucose, Onset to Treatment Time, NIHSS [DRAGON]; Totaled Health Risks in Vascular Events [THRIVE]; our new model; and a model with National Institutes of Health Stroke Scale and age) had similar area under receiver operator characteristic curves (AUROCC) to predict sICH (P for difference >0.05). The simplest model (with covariates National Institutes of Health Stroke Scale and age) predicted both sICH (AUROCC, 0.63; 95% CI, 0.58-0.68) and poststroke poor functional outcome (AUROCC, 0.80; 95% CI, 0.77-0.82) similarly to complex models. There was no evidence that the effect of r-tPA in patients at high predicted risk of sICH or poor functional outcome after stroke was less than in those at lower risk. CONCLUSIONS: There is a clinically relevant net positive effect of r-tPA in patients with acute stroke at a high predicted risk of sICH or poor functional outcome. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
BACKGROUND AND PURPOSE: Intravenous recombinant tissue-type plasminogen activator (r-tPA), despite a risk of early symptomatic intracranial hemorrhage (sICH), is of net clinical benefit to acute stroke patients. We tested if predictive models could identify patients least likely to be harmed by sICH or those who gained no net benefit. METHODS: We used the Third International Stroke Trial (IST-3) trial data set, an international, multicenter, open treatment randomized trial of 0.9 mg/kg r-tPA versus control in 3035 patients with acute ischemic stroke. We compared the discrimination and calibration of previously developed predictive models for ICH and poststroke poor outcome and developed a new model using variables selected by systematic review. We calculated the absolute and relative risk reduction of death or dependency with r-tPA in patients at a low, medium, or high predicted risk of sICH or poor functional outcome. RESULTS: Prediction models for sICH or poor outcome (Hemorrhage After Thrombolysis [HAT]; Sugar, Early Infarct Signs, Dense Artery, Age, National Institutes of Health (NIH) Stroke Score (SEDAN); Glucose Race Age Sex Pressure Stroke Severity [GRASPS]; Stroke Thrombolytic Predictive Instrument; Dense Artery, Rankin Score, Age, Glucose, Onset to Treatment Time, NIHSS [DRAGON]; Totaled Health Risks in Vascular Events [THRIVE]; our new model; and a model with National Institutes of Health Stroke Scale and age) had similar area under receiver operator characteristic curves (AUROCC) to predict sICH (P for difference >0.05). The simplest model (with covariates National Institutes of Health Stroke Scale and age) predicted both sICH (AUROCC, 0.63; 95% CI, 0.58-0.68) and poststroke poor functional outcome (AUROCC, 0.80; 95% CI, 0.77-0.82) similarly to complex models. There was no evidence that the effect of r-tPA in patients at high predicted risk of sICH or poor functional outcome after stroke was less than in those at lower risk. CONCLUSIONS: There is a clinically relevant net positive effect of r-tPA in patients with acute stroke at a high predicted risk of sICH or poor functional outcome. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren Journal: Lancet Date: 2007-01-27 Impact factor: 79.321
Authors: William N Whiteley; Karsten Bruins Slot; Peter Fernandes; Peter Sandercock; Joanna Wardlaw Journal: Stroke Date: 2012-09-20 Impact factor: 7.914
Authors: D Strbian; T Sairanen; A Meretoja; J Pitkäniemi; J Putaala; O Salonen; H Silvennoinen; M Kaste; T Tatlisumak Journal: Neurology Date: 2011-06-29 Impact factor: 9.910
Authors: Inke R König; Andreas Ziegler; Erich Bluhmki; Werner Hacke; Philip M W Bath; Ralph L Sacco; Hans C Diener; Christian Weimar Journal: Stroke Date: 2008-04-10 Impact factor: 7.914
Authors: Benedikt Frank; James C Grotta; Andrei V Alexandrov; Erich Bluhmki; Patrick Lyden; Atte Meretoja; Nishant K Mishra; Ashfaq Shuaib; Nils G Wahlgren; Christian Weimar; Kennedy R Lees Journal: Stroke Date: 2013-02-06 Impact factor: 7.914
Authors: Peter Sandercock; Richard Lindley; Joanna Wardlaw; Martin Dennis; Karen Innes; Geoff Cohen; Will Whiteley; David Perry; Vera Soosay; David Buchanan; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Eivind Berge; Karsten Bruins Slot; Veronica Murray; Andre Peeters; Graeme J Hankey; Karl Matz; Michael Brainin; Stefano Ricci; Teresa A Cantisani; Gordon Gubitz; Stephen J Phillips; Arauz Antonio; Manuel Correia; Phillippe Lyrer; Ingrid Kane; Erik Lundstrom Journal: Trials Date: 2011-11-30 Impact factor: 2.279
Authors: Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Javier Mar; Jaime Masjuan; Juan Oliva-Moreno; Nuria Gonzalez-Rojas; Virginia Becerra; Miguel Ángel Casado; Covadonga Torres; María Yebenes; Manuel Quintana; Jose Alvarez-Sabín Journal: Health Qual Life Outcomes Date: 2015-03-17 Impact factor: 3.186
Authors: Yinghua Jiang; Xiang Fan; Zhanyang Yu; Zhengbu Liao; Xiao-Shu Wang; Klaus van Leyen; Xiaochuan Sun; Eng H Lo; Xiaoying Wang Journal: Front Cell Neurosci Date: 2015-10-14 Impact factor: 5.505